In Chinese adults with relapsed or refractory multiple myeloma, adding felzartamab to lenalidomide-dexamethasone lengthened median progression-free survival (18·9 vs 10·4 months; HR 0·62), but treatment-related deaths were 6% vs 2%.
RCTn = 295
He et al. Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial